ladarixin
Showing 1 - 7 of 7
Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)
Not yet recruiting
- Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
- Sotorasib
- Ladarixin
-
New York, New YorkNYU Langone Health
Apr 4, 2023
Advanced NSCLC With KRAS G12C Mutation Trial in New York (Sotorasib, Ladarixin)
Not yet recruiting
- Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
- Sotorasib
- Ladarixin
-
New York, New YorkNYU Langone Health
Apr 4, 2023
Type 1 Diabetes Trial in Pittsburgh, Frosinone, Rome (Ladarixin, Placebo)
Recruiting
- Type 1 Diabetes
- Ladarixin
- Placebo
-
Pittsburgh, Pennsylvania
- +2 more
Nov 21, 2022
Type I Diabetes Trial in Pittsburgh (Ladarixin, Placebo)
Withdrawn
- Type I Diabetes
- Ladarixin
- Placebo
-
Pittsburgh, PennsylvaniaInstitute of Cellular Therapeutics Allegheny Health Network
Jan 17, 2022
no Condition Trial in Arzo (Ladarixin)
Completed
- no Condition
- Ladarixin
-
Arzo, Canton Ticino, SwitzerlandCROSS Research S.A., I Unit
Jan 10, 2022
Diabetes, Insulin-Dependent Trial in Belgium, Germany, Italy (Ladarixin, Placebo)
Completed
- Diabetes Mellitus, Insulin-Dependent
- Ladarixin
- Placebo
-
Brussels, Belgium
- +7 more
Sep 23, 2021
New-onset type1 Diabetes Trial in Worldwide (Ladarixin, Placebo)
Recruiting
- New-onset type1 Diabetes
- Ladarixin
- Placebo
-
Birmingham, Alabama
- +57 more
Nov 21, 2022